Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Auranofin: experience to date.

R C Blodgett

    The American Journal of Medicine
    |December 30, 1983
    PubMed
    Summary

    Auranofin, an oral rheumatoid arthritis treatment, shows superior efficacy and safety compared to placebo. This gold-containing medication offers clinical improvement with lower blood gold levels than injectable gold therapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effect of chrysotherapy on the lower gastrointestinal tract: a review.

    Seminars in arthritis and rheumatism·1987
    Same author

    Long-term efficacy and safety of auranofin: a review of clinical experience.

    Scandinavian journal of rheumatology. Supplement·1986
    Same author

    Proteinuria in gold-treated rheumatoid arthritis.

    Annals of internal medicine·1984
    Same author

    Auranofin: a unique oral chrysotherapeutic agent.

    Seminars in arthritis and rheumatism·1984
    Same author

    The musculoskeletal manifestations of acne fulminans.

    The Journal of rheumatology·1981
    Same author

    Empyema and rheumatoid pleuropulmonary disease.

    Annals of internal medicine·1978

    Area of Science:

    • Pharmacology
    • Rheumatology
    • Drug Development

    Background:

    • Rheumatoid arthritis (RA) is a chronic autoimmune disease requiring effective treatment.
    • Parenteral gold compounds have been used for RA, but possess unique characteristics.
    • Auranofin presents an oral alternative with distinct chemical and pharmacokinetic properties.

    Purpose of the Study:

    • To evaluate the efficacy and safety of auranofin in rheumatoid arthritis patients.
    • To compare auranofin's clinical outcomes with placebo and parenteral gold therapy.
    • To highlight the unique characteristics of auranofin in RA management.

    Main Methods:

    • Clinical trials involving over 3,000 patients across 27 countries.
    • Administration of auranofin at 3 mg twice daily.
    • Comparison of auranofin against placebo and gold sodium thiomalate.

    Main Results:

    • Auranofin demonstrated superior clinical improvement compared to placebo.
    • Treatment with auranofin achieved clinical benefits with lower blood gold concentrations than parenteral gold.
    • Auranofin exhibited similar efficacy but greater safety than gold sodium thiomalate.

    Conclusions:

    • Auranofin is an effective oral treatment for rheumatoid arthritis.
    • The drug offers a favorable safety profile and efficacy comparable to injectable gold therapies.
    • Long-term patient data suggests sustained benefits and tolerability.

    Related Experiment Videos